PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Hepatology. Author manuscript; available in PMC 2010 November 9.
Published in final edited form as:
PMCID: PMC2976580
NIHMSID: NIHMS242280

Indocyanine Green Elimination Test in Orthotopic Liver Recipients

Abstract

Objective

To determine its predictive capability on graft quality and resultant clinical outcome, the indocyanine green (ICG) elimination test was performed by a spectrophotometric method and a noninvasive finger-piece method with 50 orthotopic liver transplantations.

Background

Early detection of poor-functioning hepatic grafts is one of the most important issues in liver transplantation, but no reliable methods exist.

Methods

The ICG test was performed after 50 orthotopic liver transplantations on postoperative days 1,3, and 7. Indocyanine green elimination constants (KICG) were measured by both a standard spectrophotometric analysis (KICG-B) and by a finger-piece method (KICG-F). The patients were followed for a minimum of 3 months after transplantation. Results of ICG tests were correlated with various clinical determinations.

Results

Twelve of the 50 grafts were lost within three months, of which 7 were related to graft failure. Multivariate analysis using the Cox proportional hazard model revealed that KICG on postoperative day 1 was a better predictor of liver-related graft outcome than any of the conventional liver function tests. Furthermore, KICG values showed significant correlation with the severity of preservation injury, longer intensive care unit (ICU) and hospital stay, prolonged liver dysfunction, and septic complications. Correlation of KICG values by the spectrophotometric method with those by the finger-piece method was highly satisfactory in the grafts that had KICG-B <0.15 min−1 (y = 0.868x −0.011, r = .955).

Conclusion

The ICG elimination test, conducted spectrophotometrically or optically on the day after liver transplantation, is a reliable indicator of graft quality and subsequent graft outcome early after liver transplantation.

Despite significant improvements in patient outcome after orthotopic liver transplantation, primary nonfunctioning and/or poor functioning grafts in the immediate postoperative period remain an important problem.1,2 A reliable method to evaluate graft viability and to predict graft outcome in the perioperative period is needed; however, conventional liver function tests have limited reliability3,4 and the results of various quantitative liver function tests have been conflicting. 510

Recently, the indocyanine green (ICG) elimination test has been suggested as a predictor of graft viability and outcome, but its significance has not been fully clarified.57,11,12 The primary goal of this study was to determine whether the ICG elimination test can predict graft viability and outcome in the early postoperative period. The secondary goal of this study was to evaluate the applicability of a new noninvasive optical finger-piece method13 against the conventional spectrophotometric method for ICG determination.

MATERIALS AND METHODS

Case Material

From May 1, 1994 to October 31, 1994, 126 orthotopic liver transplantations were performed in 120 adult patients at Presbyterian University Hospital, Pittsburgh, PA. Of these, 50 liver transplantations in 47 patients were randomly chosen for this study. There were 26 male and 21 female patients with a median age of 53 years, ranging from 31 to 73 years. Of 43 patients who received a primary graft, 3 underwent liver retransplantation in the early posttransplantation period because of problems with the graft. The remaining 4 patients entered the study with replacement of a graft that had been transplanted previously.

Operative Procedure

Cadaveric liver grafts were harvested by a flexible multiple organ procurement technique described elsewhere.14 Median cold ischemia time of the liver was 12.1 hours, ranging from 7.6 to 25.0 hours. Recipient hepatectomy and liver replacement were performed by the standard technique in 30 cases and by the piggyback method in 20 cases.15 Median warm ischemia time of the graft was 50 minutes, ranging from 28 to 68 minutes.

Postoperative Management

Postoperative immunosuppression was with tacrolimus and steroids. The rationale for dose adjustment of these agents and supplementary administration of steroids, azathioprine, or OKT3 have been described elsewhere.2

Causes of graft malfunction were investigated by pathological, radiological, and microbiological studies.1 Graft rejection was diagnosed from clinical findings followed by histopathology of needle liver biopsies. Vascular complications were examined by Doppler ultrasonography, followed by abdominal angiography when indicated. Percutaneous transhepatic cholangiography or T-tube cholangiography was performed in cases with possible biliary problems. Whenever infectious complications were suspected, the blood, sputum, urine, peritoneal fluid, and abdominal wound discharge were cultured to identify causative microorganisms.

ICG Study

Indocyanine green elimination tests were simultaneously performed by the standard spectrophotometric method and with the optical finger-piece method. The study was performed with the approval of the Institutional Review Board. Consent forms were obtained from all of the study participants. The results of the ICG tests were blinded to the attending physicians who manage liver recipients.

Standard Method

On the mornings of postoperative days 1, 3, and 7, ICG (Cardio-green, Hynson, Westcott & Denning, Baltimore, MD) at a dose of 0.5 mg/kg was given as an intravenous bolus through a peripheral vein. Two milliliters of blood was collected via an arterial or central venous line 5, 7, 10, and 15 minutes after ICG injection. After two-fold dilution of the plasma with saline, ICG absorbance was measured using a UV/VIS spectrophotometer (Lambda 1, Per-kin-Elmer, Norwalk, CT) at 805 nm and 900 nm. The correction for blank density of the plasma was performed by the method of Nielsen.16 The ICG plasma elimination data were fitted to a monoexponential equation using a log-linear least square method. Indocyanine green elimination rate constant (KICG-B), which represented the slope of the exponential equation, was used as a representative parameter of ICG elimination.

Optical Finger-Piece Method

An ICG clearance meter (RK-1000, Sumitomo Electric, Osaka, Japan) was used to optically measure ICG elimination. A finger-piece optical sensor was adopted onto the tip of the index finger of the arm not being used for ICG injection, and the lead wires were connected to a microcomputer. The optical sensor was composed of a pair of light-emitting diodes and a photo diode, by which faint changes in ICG concentration in the fingertip could be monitored as changes in sensor signal voltage per second. The ICG elimination rate constant (KICG-F) was calculated automatically using the 600 data obtained between 5 minutes and 15 minutes after ICG injection.13

Clinical Determinations

The clinical course of all recipients was followed for a minimum of 3 months after transplantation. Information on the donor, operative procedure, postoperative graft function, and graft outcome were prospectively collected for each transplantation. Routine liver function tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), prothrombin time (PT), and total bilirubin, were serially followed. Information on intensive care unit (ICU) and hospital stay, cause of graft loss and patient death, histological severity of graft rejection and preservation injury, and the occurrence of sepsis were also recorded. Graft losses were classified into two groups: those resulting from graft failure with final total bilirubin greater than 10 mg/dL, and others caused by technical failure or extrahepatic reasons. Prolonged postoperative liver dysfunction was defined by total bilirubin greater than 5 mg/dL at postoperative day 14. The severity of graft rejection and preservation injury was evaluated by a single pathologist and subjectively graded as none, mild, moderate, and severe. Finally, sepsis was diagnosed according to the Critical Care Medicine Consensus Conference.17

Statistics

Continuous data were presented as median and ranges, and comparisons between groups were performed using the Mann-Whitney U test or the Kruskal-Wallis test. Categorical data are presented as a percentage, and the difference was evaluated by the χ2 test. Correlation was tested by means of linear regression analysis. To determine independent variables that were significantly related to the elected end-points, univariate analysis was performed to enter the Cox proportional hazard model for stepwise logistic regression analysis, followed by forward stepwise multivariate analysis using the univariate significant variables. These statistical analyses were performed using the statistical software packages Statistica (StatSoft, Tulsa, OK) and SPSS (SPSS Inc., Chicago, IL).

RESULTS

Graft Outcome

After a 3-month follow-up, 38 (35 primary grafts and 3 of the retransplanted grafts) of 50 grafts were functioning (group I). Three-month graft survival was 76% (38/50), and patient survival was 81% (38/47). Twelve grafts were lost to retransplantation or patient death, of which seven were related to graft failure (group IIA), and 5 were caused by technical or extrahepatic reasons (group IIB). Table 1 summarizes the causes of the 12 graft losses. Of the parameters studied with the donor, recipient, and operative procedure, only old donor age was significantly related to poor graft outcome. The median age and range of the liver donors in group I was: 39 (11 to 63) years old; group IIA: 59 (31 to 69) years old; and group IIB: 32 (6 to 43) years old. Group IIA was significantly disadvantaged (P = .0089).

TABLE 1
Causes of Graft Loss and Mortality in 12 Group-II Patients

Other Clinical Results

Median duration of ICU stay was 11 days. Twenty patients (40%) stayed in the ICU longer than 7 days, and 10 more patients (20%) died while in the ICU. Mean hospitalization was 44 days. Sixteen patients (32%) required hospitalization for more than 30 days, and 13 other patients (26%) could not be discharged from the hospital. Total bilirubin decreased to <5 mg/dL within 14 days in 35 grafts (70%), but 15 grafts (30%) showed prolonged graft dysfunction or graft failure. By histological study of liver biopsy specimens or removed grafts, 35 grafts (70%) had preservation injury, with moderate to severe grade in 20 (40%). Histological evidence of graft rejection was diagnosed in 22 grafts (44%), of which 6 were graded moderate to severe. Twelve grafts (24%) developed septic complications caused by bacteria (n = 9) or fungi (n = 3).

ICG Elimination Test

A total of 146 ICG injections were performed in this study. None of the patients developed hypotension, dyspnea, headache, or rash, abrupt worsening of graft function, or any other side effects. When the 50 ICG-studied grafts were compared with 67 grafts that received no ICG tests during the study period, there were no statistical differences in graft and patient survival and postoperative changes in routine liver function tests.

Figure 1 illustrates the correlation of indocyanine green elimination constant (KICG) values determined by the KICG-B method and the KICG-F method. Irrespective of postoperative days on which the ICG tests were performed, both measurements showed highly significant correlation (y = 0.861x −0.009, r = .886, n = 146). If KICG-B was >0.15 min−1 and KICG-F was >0.12 min−1, the correlation between the two was rather scattered (y = 0.533x + 0.055, r = .323, n = 68), because KICG-F values fluctuated at this or higher levels. At lower levels, however, both KICG-B and KICG-F had an almost linear correlation (y = 0.868x − 0.011, r = .955, n = 78).

FIG. 1
Relationship between KICG-B and KICG-F. Data represent all 146 ICG elimination tests. See text for linear regression.

KICG and Clinical Outcome

Postoperative changes in KICG of individual patients from the three groups are shown in Fig. 2, where KICG levels are arbitrarily divided into three classes: class A (KICG-B > 0.10 min−1); class B (0.10 min−1 > KICG-B > 0.06 min−1); and class C (KICG-B < 0.06 min−1). Using the equation determined with lower KICG-B values, KICG-B at 0.10 min−1 and 0.06 min−1 corresponded to KICG-F at 0.075 min−1 and 0.04 min−1, respectively. On postoperative day (POD) 1, 32 of the 38 group I patients (84%) had KICG in class A, whereas all of the group IIA patients were either class B (3/7) or class C (4/7). Graft failure occurred in 0% (0/36) of class A, 30% (3/10) of class B, and 100% (4/4) of class C when classified by KICG on POD 1. After POD 1, KICG of most group I patients remained high, but that of group IIA and group IIB showed further reductions. Of the 20 grafts that showed moderate to severe preservation injury on needle biopsy or removed graft, one patient died of primary nonfunction at POD 2, and 17 grafts had KICG at class B or class C on POD 3. The incidence of moderate to severe preservation injury was 7.1% (2/28) of class A, 66.7% (8/12) of class B, and 100% (9/9) of class C by KICG on POD 3 (Fig. 3A). Similarly, the incidence of sepsis was 3.6% (1/28) of class A, 80% (8/10) of class B, and 75% (3/4) of class C by KICG on POD 7 (Fig. 3B).

FIG. 2
Changes in KICG-B levels of liver recipients with a functioning graft (group I) or graft loss from either graft failure (group IIA) or liver-unrelated reasons (group IIB).
FIG. 3
Correlation of KICG-B with (A) histological preservation injury and (B) the occurrence of septic complications.

KICG and Liver Function Tests

Correlation of KICG-B levels with those of AST, ALT, PT, and total bilirubin on POD 1 is shown in Fig. 4. Although both AST (y = −7759x + 3238, r2 = .02, not significant) and ALT (y = −675x + 975, r2 = .00, not significant) were not correlated, PT (y = −27.3x + 21.1, r2 = .18, P < .005) and total bilirubin (y = −66.lx + 18.1, r2 = .36, P < .001) values had an inverse relationship with KICG-B. However, in contrast to KICG-B, higher PT and total bilirubin on POD 1 did not always reflect poor outcome of transplanted grafts.

FIG. 4
Correlation of KICG-B levels with (A) AST, (B) ALT, (C) total bilirubin, and (D) prothrombin time on POD 1. Group I: patients with a functioning graft; group IIA: patients with graft loss caused by graft failure; and group IIB: liver-unrelated graft loss. ...

Correlation of KICG and Liver Function Tests With Clinical Outcome

Correlation of various clinical outcomes with the results of the ICG elimination test and routine liver function tests was examined (Table 2). Using a univariate analysis, KICG values determined both spectrophotometrically and optically showed significant correlation with all determinants except for nonliver-related graft loss and rejection. Of the routine liver function tests, total bilirubin level and highest PT within 7 postoperative days reflected the incidence of overall and liver-related graft loss. The highest levels of ALT, AST, PT, and total bilirubin correlated with preservation injury. When multivariate analysis was applied, KICG-B at POD 1 was the best indicator for overall and liver-related graft loss, and KICG-F at POD 7 reflected prolonged hospitalization. The incidence of liver-unrelated graft loss and graft rejection was unpredictable using any of these parameters.

TABLE 2
Correlation of KICG and Liver Function Tests With Clinical Outcome After 50 Orthotopic Liver Transplantations

DISCUSSION

Causes of primary non function and dysfunction in hepatic allografts after orthotopic transplantation are multifactorial. The risk factors include age, gender, and medical condition of the donor, cause and severity of the recipient’s liver disease, cold ischemia time and warm ischemia time of the graft, difficulty and amount of blood transfused during surgery, and blood type and immunological compatibility between the donor and the recipient. Whatever the causes, 5% of the grafts require urgent retransplantation, and 15% of the grafts need prolonged management for survival, because of poor initial graft function.14 A reliable method enabling early determination of such grafts is crucial.

Clinically, malfunction of hepatic allografts is predicted if the recipients remain unconscious, hypotensive, and oliguric or anuric after transplantation. The grafts make small amounts of pale bile. Laboratory findings, including acidosis, hypoglycemia, PT prolongation, elevated liver enzymes, and high bilirubin level, are supportive of the diagnosis of irreversible graft damage, but are not always conclusive. With the aid of clinical chemical, histological and radiological studies, the decision to regraft is made mostly from the experience of the liver transplantation surgeons.1

A few quantitative functional tests have been proposed for determining posttransplant graft quality. However, each has limitations per se in terms of sensitivity, specificity, and practicality. For instance, biochemical recovery of hepatocyte energy metabolism18 and serum amino acids profile19 after liver transplantation correlates with the quality of the graft, but the determination is too complex and takes too long to apply clinically. Some investigators5,8 have reported that measurement of monoethylglycin-exylidide (MEGX) formation after intravenous lidocaine administration is a good predictor of graft function. However, because lidocaine is metabolized by the drug-metabolizing enzyme P-450,20 the rate of formation could be influenced by the medications routinely used after liver transplantation such as immunosuppressants, steroids, antibiotics, and calcium ion channel blockers. The rate of MEGX formation can also be affected by extrahepatic lidocaine metabolism.21 In this study, MEGX was determined by a high-pressure liquid chromatography method simultaneously with the ICG elimination test (Fig. 5). Although the correlation between KICG-B and MEGX was highly significant (y = 276x + 13, r2 = .28, P < .001), a low MEGX value did not predict poor graft outcome when compared with low KICG-B. Arterial ketone body ratio, which reflects the redox state of hepatocytes, has limitations for routine clinical use because of the need for glucose loading before measurements, and of the exclusion of diabetic patients.10 A recent report has indicated that AKBR may be influenced by extrahepatic metabolism of the ketone bodies.22

FIG. 5
Correlation of KICG-B levels with MEGX on POD 1. MEGX value was calculated by subtracting the 0-minute value from the 30-minute value. Group I: patients with a functioning graft; group IIA: patients with graft loss caused by graft failure; and group IIB: ...

The present investigation was conducted to study whether the ICG elimination test can safely be used as a predictor of graft quality after liver transplantation in patients. The results suggest that low KICG levels (<0.06 min−1 using KICG-B and <0.04 min−1 using KICG-F), especially on POD 1 after transplantation, is a good indicator of graft failure and subsequent graft loss, In addition, continued suppression of KICG (<0.10 min−1 by KICG-B and <0.075 min−1 by KICG-F) during the early postoperative period of 7 days was found to be closely associated with the severity of preservation injury, prolonged liver dysfunction, or septic complication, and resulting longer ICU and hospital stay. Irrespective of postoperative days and graft quality, administration of ICG to recipients, at a dose of 0.5 mg/kg, had no detrimental effect on graft survival and function of hepatic allografts.

Because of its safety and negligible extrahepatic elimination, the ICG test has been used, by either bolus injection or continuous infusion, to medically determine the functional capacity of diseased livers.23,24 In the field of general surgery, it has also been used to predict the outcome of patients with liver abnormalities before and/or after major hepatic resections.25,26 Recently, the application of ICG testing has gradually expanded to liver transplantation.57,11,12 While the ability of ICG test results to predict short-term graft outcome is controversial when applied to donors before procurement,11,12 this test has been reported to have some prognostic power when used in smaller numbers of patients after liver transplantation. 5,6 This finding has been confirmed by our study. As a primary cutoff value for predicting graft failure, Lamesch et al.5 used an ICG half-life of 12 minutes, and Jalan et al.6 selected an ICG clearance of 200 mL/min. These figures correspond well to our cutoff of KICG-B at 0.06 min−1 and KICG-F at 0.04 min−1, assuming an average plasma volume of 50 mL/kg and body weight of 70 kg. In addition, most of the failed grafts in the Lamesch series had an ICG half-life greater than 7 minutes which is equivalent to our secondary cutoff levels of KICG-B at 0.10 min−1 and KICG-F of 0.075 min−1.

KICG is a function of hepatic blood flow, hepatic dye clearance, and plasma volume; however, hepatic blood flow is the major determinant of KICG in normal livers.27 During the immediate postoperative period, plasma volume appears to have little influence on KICG levels, because plasma volume is expanded as a result of fluid and blood supplementation during and after surgery. Although hepatic blood flow in functioning liver grafts after transplantation was reported to increase by persistent hyperdynamic circulation and hepatic denervation,2830 KICG levels on POD 1 of group I grafts, most of which had no to mild preservation injury (KICG-B: 0.169 [0.087 – 0.253], n = 26) were slightly lower than those of normal healthy volunteers (KICG-B: 0.187 [0.160–0.247], n = 20). The difference may reflect the presence of hepatocyte dysfunction even in well-functioning grafts caused during procurement, preservation, and transplantation. Although not investigated in this study, lower KICG levels with group IIA grafts appeared to reflect decreased hepatic blood flow rather than hepatocyte damage because there was no correlation between values of KICG and released liver enzymes. Recent experimental studies have shown that hypothermic preservation of the liver causes greater damage to the micro-vasculature than to the hepatocytes.31 Using a microfil perfusion technique, we have previously shown that microcirculatory damage is augmented after graft reperfusion causing stagnation, pooling, and a filling-defect in the sinusoids, as well as a reduction in hepatic blood flow, particularly in arterial flow.32 Studies aimed at expanding the microvasculature during liver preservation33 or modulation of vasoactive substances34 were shown to improve hepatic blood flow, ICG elimination, and graft function after reperfusion. Further study on the role of hepatic blood flow in the determination of KICG levels and posttransplant graft function is needed.

Lower KICG levels were not only related to poor outcome and preservation injury, but were also associated with septic complications, delayed graft function, and longer ICU and hospital stays. However, neither KICG levels nor liver function tests correlated with the incidence of graft rejection. This is in contrast to the observation by Howard et al.35 who reported that the incidence of rejection was higher in patients with “severe preservation injury” estimated by higher AST level after transplantation. The potent tacrolimus-based immunosuppression used with our patients may have concealed the effect of preservation injury on graft rejection.

Along with the standard spectrophotometric analysis, a new optical finger-piece method was used in this study to evaluate whether the latter can simplify the ICG elimination test and yet provide reliable results. Although KICG-F values were more widely dispersed at higher levels and were consistently lower at lower levels than those of KICG-B, both measurements showed strong correlation. The differing behavior of KICG-F in the higher and lower range may reflect changes in systemic or peripheral hemodynamics that invariably occur after liver transplantation and accompany the use of vasoactive agents and/or immunosuppressants. Whatever the reason, the fluctuation in KICG-F appears to be insignificant clinically, because lower KICG-F values always indicated lesser quality of hepatic allografts in our study. More importantly, this novel method has advantages in simplicity, noninvasiveness, real-time presentation of test results, and cost-effectiveness.13 The optical finger-piece method also eliminates the need for serial blood samplings, their preparations, and actual measurements that are required for the standard spectrophotometric assay. In addition, the finger-piece method may be superior to the classic ear densitometry36 in terms of short idling or calibration time, better baseline stability, and better fitness. The results of this study warrant a large scale investigation into the suitability of ICG for predicting outcome not only of the grafts after operation, but also of the patients awaiting liver transplantation.

Acknowledgment

We are grateful to Ilene Felser, R.N., B.S.N, for her enthusiastic cooperation in carrying out this protocol, and to Kunio Awazu, M.D. for meaningful discussion concerning the ICG finger-piece method.

Aided by Research Grants from the Veterans Administration, Pittsburgh, PA and Project Grant No. DK-29961 from the National Institutes of Health, Bethesda, MD.

Abbreviations

ICG
indocyanine green
KICG-B
indocyanine green elimination constant measured by a standard spectrophotometric analysis
KICG-F
indocyanine green elimination constant measured by a finger-piece method
AST
aspartate aminotransferase
ALT
alanine aminotransferase
PT
prothrombin time
ICU
intensive care unit
KICG
indocyanine green elimination constant
POD
postoperative day
MEGX
monoethylglycin-exylidide

REFERENCES

1. Starzl TE, Demetris AJ. Liver transplantation. Chicago, IL: Chicago: Year Book Medical Publishers, Inc; 1990. pp. 1–194.
2. Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, et al. Liver kidney and thoracic organ transplantation under FK506. Ann Surg. 1990;212:295–307. [PubMed]
3. Furukawa H, Todo S, Imventarza O, Casavilla A, Wu YM, scotti-Foglieni C, Broznick B, et al. Effect of cold ischemia time on the early outcome of human heptic allografts preserved with UW solution. Transplantation. 1991;51:1000–1004. [PMC free article] [PubMed]
4. Doyle HR, Marino IR, Jabbour N, Zetti G, McMichael J, Mitchell S, Fung J, et al. Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation. 1994;57:1028–1036. [PMC free article] [PubMed]
5. Lamesch P, Ringe B, Oellerich M, Burdelski M, Beyrau R, Gubernatis G, Pichlmayr R. Assessment of liver function in the early postoperative period after liver transplantation with ICG MEGX and GAL tests. Transplant Proc. 1990;22:1539–1541. [PubMed]
6. Jalan R, Plevris JN, Jalan AR, Niall J, Finlayson C, Hanes PC. A pilot study of indocyanine green clearance as an early predictor of graft function. Transplantation. 1994;58:196–200. [PubMed]
7. Clements D, McMaster P, Elias E. Indocyanine green clearance in acute rejection after transplantation. Transplantation. 1988;46:383–385. [PubMed]
8. Potter JM, Hickman PE, Lynch SV, Henderson A, Wright M, Balderson G, Strong RW. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient. Transplantation. 1993;56:1385–1388. [PubMed]
9. Nagel RA, Dirix LY, Hayllar KM, Preisig R, Tredger JM, Williams R. Use of quantitative liver function tests—caffeine clearance and galactose elimination capacity—after orthotopic liver transplantation. J Hepatol. 1990;10:149–157. [PubMed]
10. Asonuma K, Takaya S, Selby R, Okamoto R, Yamamoto Y, Yokoyama T, Todo S, et al. The clinical signficance of the arterial ketone body ratio as an early indicator of graft viability in human liver transplantation. Transplantation. 1991;51:164–171. [PMC free article] [PubMed]
11. Oellerich M, Buldelski M, Ringe B, Lamesch P, Gubernatis G, Bunzendahl H, Pichlmayr R, et al. Lignocaine metabolite formation as a measure of pretransplant liver function. Lancet. 1989;2:640–642. [PubMed]
12. Koneru B, Leevy CB, Klein KM, Zweil P, Wilson DJ. Indocyanine green clearance in the evaluation of donor livers. Transplant Proc. 1993;25:1919–1920. [PubMed]
13. Ishigami Y, Masuzawa M, Miyoshi E, Kato M, Tamura K, Kanda M, Awazu K, et al. Clinical applications of ICG finger monitor in patients with liver disease. J Hepatol. 1993;19:232–240. [PubMed]
14. Starzl TE, Hakala TR, Shaw BW, Jr, Hardesty RL, Rosenthal TJ, Griffith BP, Iwatsuki S, et al. A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Ostet. 1984;8:223–230. [PMC free article] [PubMed]
15. Tzakis A, Todo S, Starzl TE. Piggyback orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg. 1989;210:649–652. [PubMed]
16. Nielsen NC. Spectrophotometric determination of indocyanine green in plasma especially with a view to an improved correction for blank density. scand J Clin Lab Invest. 1963;15:613–621. [PubMed]
17. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis; Crit Care Med; 1992. pp. 864–874. [PubMed]
18. Hamamoto I, Takaya S, Todo S, Fujita S, Nakamura K, Irish WD, Starzl TE. Can adenine nucleotides predict primary nonfunction of the human liver homograft? Transplant International. 1994;7:89–95. [PMC free article] [PubMed]
19. Clowes GH, Jr, Pearl RH, Bosari S, Jenkins RL, Khettry U. Correlation of amino acid metabolism and liver biopsies in preoperative and postoperative patients receiving hepatic transplants. Transplant Proc. 1987;19:2462–2463. [PubMed]
20. Bargetzi MY, Aoyama T, Gonzalez FJ, Meyer VA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther. 1989;46:521–527. [PubMed]
21. Sallie RW, Tredger JM, Williams R. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX) Biopharm Drug Dispos. 1992;13:555–558. [PubMed]
22. Matsushita K, Kawasaki S, Makuuchi M. Arterial ketone body ratio in liver surgery. Hepatology. 1994;20:331–335. [PubMed]
23. Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology. 1991;14:1029–1034. [PubMed]
24. Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, Sacerdati D, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology. 1992;102:973–979. [PubMed]
25. Hemming AW, schdamore CH, Shackleton CR, Pudek M, Erb SR. Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg. 1992;163:515–518. [PubMed]
26. Yamanaka N, Okamoto E, Oriyama T, Fujimoto J, Furukawa K, Kawamura E, Tanaka T, et al. A prediction scoring system to select the surgical treatment of liver. Further refinement based on 10 years of use. Ann Surg. 1994;219:342–346. [PubMed]
27. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharm Therap. 1975;18:377–390. [PubMed]
28. Hadengue A, Lebrec D, Moreau R, Sogni P, Durand F, Caudin C, Bernuau J, et al. Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology. 1993;17:175–178. [PubMed]
29. Henderson JM, Millikan WJ, Hooks M, Noe B, Kutner MH, Warren WD. Increased galactose clearance after liver transplantation: A measure of increased blood flow through the denervated liver? Hepatology. 1989;10:288–291. [PubMed]
30. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, Bosch J, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology. 1993;17:355–360. [PubMed]
31. Clavien PA, Harvey PRC, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation. 1992;53:957–978. [PubMed]
32. Furukawa H, Wu YM, Zhu Y, Suzuki T, Todo S, Starzl TE. Disturbance of microcirculation associated with prolonged preservation of dog livers under UW solution. Transplant Proc. 1993;25:1591–1592. [PMC free article] [PubMed]
33. Zeng Q-H, Toclo S, Murase N, Zhang S, Doria C, Nakamura K, Azzarone A, et al. Modified simple cold storage of rat livers with UW solution. Transplantation. 1994;58:408–414. [PMC free article] [PubMed]
34. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusioh injury. Hepatology. 1995;21:1138–1143. [PubMed]
35. Howard TK, Klintmalm GBG, Gofer JB, Husberg BS, Goldstein RM, Gonwa TA. The influence of preservation injury on rejection in the hepatic transplantation recipient. Transplantation. 1990;49:103–107. [PubMed]
36. Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM. Indocyanine green clearance as a test for hepatic function. Evaluation by dichromatic ear densitometry. JAMA. 1967;200:236–240. [PubMed]